百奥泰：2025年预计营收9 - 9.7亿元，净亏损减少

Core Viewpoint - The company expects to achieve revenue of 900 to 970 million yuan in 2025, indicating an increase of 157 to 227 million yuan compared to the previous year [1] Financial Performance - The net profit attributable to the parent company is projected to be between -280 to -390 million yuan, representing a reduction in losses by 120 to 230 million yuan [1] - The non-GAAP net profit is expected to range from -380 to -490 million yuan, which will decrease losses by 66 to 176 million yuan [1] Market Expansion - The reduction in losses is attributed to the company's market expansion efforts, including increased sales of Adalimumab and Tocilizumab [1] - The launch of Ustekinumab in the United States and growth in licensing and sales revenue also contributed to the improved financial outlook [1]